Taiwan Universe BioMedicine Inc.
Selected as a startup company by FINDIT Matchmaking in the past two years
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Main Product
Innovative platform of enterovirus and influenza VLP vaccines
Promising option to combat viruses mutation
Provide a broad-spectrum prevention with better immunogenicity
Enable faster scaling-up
Innovative platform of enterovirus and influenza VLP vaccines
Promising option to combat viruses mutation
Provide a broad-spectrum prevention with better immunogenicity
Enable faster scaling-up
The content above was translated by Ai
Founded Year
2023
Unified Business No.
94247033
Status
Active
Number of Employees
0
Total Paid-in
Capital
75,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Dr. Min-Shi Lee has more than 30 years experiences in vaccine research and development including 6 years R&D in USA vaccine company, and several national vaccine development projects of enterovirus, influenza H5N1, H7N9 and seasonal influenza. To strengthen and grow Taiwan’s vaccine business, Dr. Min-Shi Lee’s group has established a start-up company for developing bivalent enterovirus vaccines and seasonal influenza virus-like particle (VLP) vaccines and also expend to more diseases area through this innovative technology platforms.
PhD, Oxford University, UK
MPH, National Taiwan University
Investigator, NHRI, Taiwan (2005~)
Scientist, Aviron/Medimmune (1999~2005)
NIPM (former CDC), Taiwan (1993~1998)
>30 years for vaccine research including measles, JEV, influenza (FluMist licensed in USA) , PIV3, and EV71 (licensed in Taiwan)
Built Asia-Pacific Network for Enterovirus Surveillance (APNES)
PhD, Oxford University, UK
MPH, National Taiwan University
Investigator, NHRI, Taiwan (2005~)
Scientist, Aviron/Medimmune (1999~2005)
NIPM (former CDC), Taiwan (1993~1998)
>30 years for vaccine research including measles, JEV, influenza (FluMist licensed in USA) , PIV3, and EV71 (licensed in Taiwan)
Built Asia-Pacific Network for Enterovirus Surveillance (APNES)
The content above was translated by Ai
